Ramucirumab: Boon or bane

Journal of the Egyptian National Cancer Institute

Volumn 28, Issue 3, 2016, Pages 133-140

  Tiwari, Priya ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Gastric cancer; Lung cancer; Ramucirumab; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; RAMUCIRUMAB; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ANEMIA; ANOREXIA; ASCITES; ASTHENIA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG MECHANISM; DRUG STRUCTURE; DYSPHAGIA; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FISTULA; GLIOBLASTOMA; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LUNG CANCER; MELANOMA; METASTATIC COLORECTAL CANCER; NAUSEA; OVARY CARCINOMA; PERFORATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOTHORAX; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; STOMACH CANCER; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING; WOUND HEALING; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; PATHOLOGY; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS; STOMACH NEOPLASMS;

EID: 84961805862     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2016.03.001     Document Type: Review

References (36)

1. [1] Spratlin, J.L., Cohen, R.B., Eadens, M., Gore, L., Camidge, D.R., Diab, S., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28:5 (2010), 780–787.
2. [2] Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278:44 (2003), 43496–43507.
3. [3] Franklin, M.C., Navarro, E.C., Wang, Y., Patel, S., Singh, P., Zhang, Y., et al. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure 19:8 (2011), 1097–1107.
4. [4] Garon, E.B., Ciuleanu, T.E., Arrieta, O., Prabhash, K., Syrigos, K.N., Pérol, M., et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:9944 (2014), 665–673.
5. [5] Doebele, R.C., Spigel, D., Tehfe, M., Thomas, S., Reck, M., Bonomi, P., et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 121:6 (2015), 883–892.
6. [6] Camidge, D.R., Berge, E.M., Doebele, R.C., Ballas, M.S., Jahan, T., Mita, A., et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 9:10 (2014), 1532–1539.
7. [7] Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Tabernero, J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (2014), 31–39.
8. [8] Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double blind, randomised phase 3 trial. Lancet Oncol 15 (2014), 1224–1235.
9. [9] Hironaka, S., Shimada, Y., Sugimoto, N., Komatsu, Y., Nishina, T., Yamaguchi, K., et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy – efficacy analysis in Japanese and Western patients. J Clin Oncol, 32, 2014 abstract 4005.
10. [10] Yoon, H., Bendell, J., Braiteh, F., Braiteh, S.F., Firdaus, I., Philip, A.P., et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): randomized, double-blind, multicenter phase 2 trial. J Clin Oncol, 32, 2014 abstract 4004.
11. [11] Tabernero, J., Yoshino, T., Cohn, A.L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:5 (2015), 499–508.
12. [12] Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30 (2012), 3499–3506.
13. [13] Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:12 (2007), 1539–1544.
14. [14] Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 26:4 (2015), 724–730.
15. [15] Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:1 (2013), 29–37.
16. [16] Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
17. [17] Van Cutsem, E., Bajetta, E., Valle, J., Köhne, C.H., Hecht, J.R., Moore, M., Germond, C., et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29 (2011), 2004–2010.
18. [18] Garcia-Carbonero, R., Rivera, F., Maurel, J., Ayoub, J.P., Moore, M.J., Cervantes, A., et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 19 (2014), 350–351.
19. [19] Zhu, A.X., Finn, R.S., Mulcahy, M., Gurtler, J., Sun, W., Schwartz, J.D., et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19 (2013), 6614–6623.
20. [20] Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol; 16: 7, 859–870.
21. [21] A Study of Ramucirumab (LY3009806) Versus Placebo in Participants with Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2). https://clinicaltrials.gov/ct2/show/NCT02435433. Last accessed on 27.12.2015.
22. [22] Garcia, J.A., Hudes, G.R., Choueiri, T.K., Stadler, W.M., Wood, L.S., Gurtler, J., et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 120:11 (2014), 1647–1655.
23. [23] Mackey, J.R., Ramos-Vasquez, M., Lipatov, O., McCarthy, N., Krasnozhon, D., Semiglazov, V., et al. Primary results of ROSE/TRIO-12, a randomized, placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 33:2 (2015), 141–148.
24. [24] Miles, D.W., Chan, A., Dirix, L.Y., Cortés, J., Pivot, X., Tomczak, P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28 (2010), 3239–3247.
25. [25] Bergh, J., Bondarenko, I.M., Lichinitser, M.R., Liljegren, A., Greil, R., Voytko, N., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30 (2012), 921–929.
26. [26] Penson, R.T., Moore, K.M., Fleming, G.F., Braly, P., Schimp, V., Nguyen, H., et al. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 134:3 (2014), 478–485.
27. [27] Hussain, M., Rathkopf, D.E., Liu, G., Armstrong, A.J., Kelly, W.K., Ferrari, A.C., et al. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. J Clin Oncol, Genitourinary Cancers Symposium, 30, 2012 (5_suppl): 97.
28. [28] Carvajal, R.D., Wong, M.K., Thompson, J.A., Gordon, M.S., Lewis, K.D., Pavlick, A., et al. A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. Eur J Cancer 50:12 (2014), 2099–2107.
29. [29] A Study of Ramucirumab (LY3009806) plus Docetaxel in Participants with Urothelial Cancer (RANGE). https://clinicaltrials.gov/ct2/show/NCT02426125. Last accessed on 28.12.15.
30. [30] Phase II Randomized Trial of FOLFIRINOX +/− Ramucirumab in Advanced Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT02581215. Last accessed on 28.12.15.
31. [31] A Study of Ramucirumab plus Pembrolizumab in Participants with Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium. https://clinicaltrials.gov/ct2/show/NCT02443324. Last accessed on 28.12.15.
32. [32] Ramucirumab for Advanced Pre-treated Biliary Cancers. https://clinicaltrials.gov /ct2/show/NCT02520141. Last accessed on 28.12.15.
33. [33] Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients with Recurrent Glioblastoma Multiforme. https://clinicaltrials.gov/show/NCT00895180. Last accessed on 28.12.15.
34. [34] Ranpura, V., Hapani, S., Wu, S., Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305 (2011), 487–494.
35. [35] Ganapathi, A.M., Westmoreland, T., Tyler, D., et al. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. J Am Coll Surg 214 (2012), 582–588 discussion 588–590.
36. [36] Bach, P.B., Ramucirumab for colon cancer and the problem of rising prices independent of benefits. Oncologist 20:9 (2015), 983–984.